Posted by Amber Stanford
June 12, 2012 – More reports were made against the controversial new blood-thinner, Pradaxa, than any other drug on the market last year. And according to the Institute for Safe Medicine Practices’ (ISMP), Pradaxa also topped the list for reports of deaths, hemorrhage, acute renal failure, and stroke. Pradaxa was released as an alternative to the more common Warfarin/Coumadin. However, unlike Warfarin, Pradaxa does not currently have an antidote in the event of excessive bleeding. The FDA launched a review of Pradaxa last December based on bleeding-related side effects, while regulators in Europe and Japan have encouraged stronger warnings. The European Medicines Agency (EMA) has more recently asked for more information regarding specific uses of Pradaxa and how to manage patients using the drug.